Abstract
The aim of this study was to conduct a cost-effectiveness analysis in terms of cost per objective response with dabrafenib+trametinib compared to vemurafenib+cobimetinib and pembrolizumab, as the first line of treatment in patients with unresectable or metastatic melanoma with BRAF V600 mutation, from the perspective of the Colombian health system.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
